CMS Open Payments · Program Year 2024
PolyNovo North America LLC
PolyNovo North America LLC reported $1,956,571.67 across General Payments, Research, and Ownership to 5,925 physicians and teaching hospitals across 7,446 transactions.
- $2.0M Top quartile payer
- All-tracks total
- 7,446 Top quartile volume
- Transactions
- 5,925 Top quartile reach
- Recipients
- +$697.6K
- General Payments vs PY2023
PolyNovo North America LLC reported $1,956,571.67 across all CMS Open Payments tracks (General + Research + Ownership) to 5,925 physicians and teaching hospitals in Program Year 2024 - ranking #453 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $827,702.00, averaging $330.22 per recipient.
How PolyNovo North America LLC's $2.0M all-tracks total breaks down
PolyNovo North America LLC's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
49/100
Total payments
F
28/100
Transaction volume
D
64/100
Physician reach
D
55/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer polynovo-north-america-llc PolyNovo North America LLC
$2.0M · #453/1,925 · 0.0% industry · PY2024
- TOT $2.0M
- RANK #453
- SHARE 0.0%
- TXN 7,446
- RCP 5,925
- CAT 4
- GEN $827.7K
- ΔGEN +$697.6K
- TOP1 11.0%
- PY 2024
Volume peers
Nearest volume peer: Alimera Sciences, Inc. ($2.0M)
PolyNovo North America LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
PolyNovo North America LLC's CMS-reported General Payments increased by $697.6K (+536.0%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: POLYNOVO NORTH AMERICA LLCPY2023: POLYNOVO NORTH AMERICA LLCPY2024: PolyNovo North America LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $130,141.87
- PY2024
- $827,702.00
What the Data Shows for PolyNovo North America LLC
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For PolyNovo North America LLC, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
5,810 transactions worth $408.0K make "Food and Beverage" the top general-payment category in the 4-category breakdown below, 49.3% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Food and Beverage" leads PolyNovo North America LLC's 4-category general-payment breakdown at $408.0K, 49.3% of the reported total.
PolyNovo North America LLC reports 4 general-payment categories - the top three are Food and Beverage (49.3%), Consulting Fee (43.8%), and Travel and Lodging (6.5%). The remaining 1 category make up 0.4% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How PolyNovo North America LLC divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $408.0K | 5,810 | 49.3% |
| Consulting Fee | $362.5K | 69 | 43.8% |
| Travel and Lodging | $53.8K | 43 | 6.5% |
| Compensation for Faculty or Speaker (Medical Education) | $3.4K | 3 | 0.4% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $288,531.76 (34.9%) of $827,702.00 in this company's General Payments records across 3,382 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for PolyNovo North America LLC
The five named recipients with the highest reported General Payments from this company
- 1
Shaun Mendenhall
$90,718.27 across 48 reported transactions
- 2
Paul Kim
$72,808.75 across 27 reported transactions
- 3
Kyle Chepla
$61,175.96 across 29 reported transactions
- 4
Mark S Granick
$33,828.78 across 16 reported transactions
- 5
William Hickerson
$30,000.00 across 6 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
PolyNovo North America LLC ranks #453 of 1,925 by total payments (top 24% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,443 of 1,838 by HHI (bottom 22% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Evolution Surgical, Inc : $74.8K total payments, HHI 324
- Sanofi Pasteur Inc. : $1.9M total payments, HHI 323
- SomnoMed Inc. : $20.8K total payments, HHI 323
- Tolmar, Inc. : $420.1K total payments, HHI 322
- Ancora Heart, Inc. : $136.9K total payments, HHI 320
- Ucb SA : $1.1M total payments, HHI 317
- PolyNovo North America LLC (this company) : $827.7K total payments, HHI 315
- Piedmont Plus Innovation : $24.7K total payments, HHI 314
- Goode Surgical Inc : $24.0K total payments, HHI 314
- Vision Quest Industries Inc. : $2.1K total payments, HHI 314
- United Orthopedics LLC : $47.9K total payments, HHI 313
- Pharmacosmos Therapeutics Inc. : $1.4M total payments, HHI 311
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as PolyNovo North America LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about PolyNovo North America LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with PolyNovo North America LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
Grifols USA, LLC
Ferring Pharmaceuticals Inc.
CooperSurgical, Inc.
PROCEPT BioRobotics Corporation
Biohaven Pharmaceutical Holding Company Ltd.
Put this to use
PolyNovo North America LLC ranks #453 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See where PolyNovo North America LLC sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just PolyNovo North America LLC. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.